Tatiana Hernández‐Guerrero

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Víctor Moreno, María Vieito, Tatiana Hernández‐Guerrero et al. · Annals of Oncology · 2020 · 66 citations · Full text

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Víctor Moreno, María Vieito, Juan Manuel Sepúlveda-Sánchez et al. · Nature Communications · 2023 · 23 citations · Full text

Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection

Maria J. de Miguel, Bernard Doger, Valentina Boni et al. · Cancer · 2020 · 15 citations · Full text

Virus Epidemiology, Cancer Patients, Covid-19 Epidemiology +21

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.

Erminia Massarelli, Ani Sarkis Balmanoukian, María Vieito et al. · Journal of Clinical Oncology · 2020 · 10 citations

Immunology, Pathology, Metronomic Chemotherapy +20

Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors

Elena Garralda, V. Moreno, G. Alonso et al. · European Journal of Cancer · 2022 · 10 citations · Full text

Class Pan-myc-inhibitor, Medicine, Pharmacology +8